BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SAPA-GP - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAPA-GP
X-ORIGINAL-URL:https://sapagp.org
X-WR-CALDESC:Events for SAPA-GP
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260320T120000
DTEND;TZID=America/New_York:20260321T183000
DTSTAMP:20260423T151455
CREATED:20250914T124113Z
LAST-MODIFIED:20260313T021404Z
UID:6121-1774008000-1774117800@sapagp.org
SUMMARY:SAPA-GP 2026 Annual Conference
DESCRIPTION:General User RegistrationSpeaker RegistrationSlides UploadScheduleSponsors
URL:https://sapagp.org/event/sapa-gp-2026-annual-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AC,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2024/08/ac26.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251120T180000
DTEND;TZID=America/New_York:20251120T210000
DTSTAMP:20260423T151455
CREATED:20251115T034532Z
LAST-MODIFIED:20251115T034724Z
UID:6219-1763661600-1763672400@sapagp.org
SUMMARY:Awareness in the "rare diseases" ecosystem
DESCRIPTION:
URL:https://sapagp.org/event/awareness-in-the-rare-diseases-ecosystem/
LOCATION:Pennsylvania Biotechnology Center\, 3805 Old Easton Rd\, Doylestown\, PA\, United States
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2025/11/pnn.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251003T080000
DTEND;TZID=America/New_York:20251004T170000
DTSTAMP:20260423T151455
CREATED:20250920T005124Z
LAST-MODIFIED:20250920T012211Z
UID:6184-1759478400-1759597200@sapagp.org
SUMMARY:APM Annual Conference
DESCRIPTION:
URL:https://sapagp.org/event/amp-annual-conference/
LOCATION:Pennsylvania Convention Center\, 1101 Arch St\,\, Philadelphia\, PA\, 19107\, United States
CATEGORIES:Event
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2025/09/APM.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250627T080000
DTEND;TZID=America/New_York:20250628T170000
DTSTAMP:20260423T151455
CREATED:20240822T013743Z
LAST-MODIFIED:20250618T125524Z
UID:5108-1751011200-1751130000@sapagp.org
SUMMARY:SAPA-GP 2025 Cell & Gene Therapy
DESCRIPTION:Click Here for Registration and More InformationMobile App
URL:https://sapagp.org/event/sapa-gp-2025-cell-gene-therapy/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AtPhilly,Event,In Person
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2024/08/2025-cgt-feature-1.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250314
DTEND;VALUE=DATE:20250316
DTSTAMP:20260423T151455
CREATED:20240822T013154Z
LAST-MODIFIED:20250320T010533Z
UID:5105-1741910400-1742083199@sapagp.org
SUMMARY:SAPA-GP 2025 Annual Conference
DESCRIPTION:General Conference RegistrationPresentation Slide Deck UploadSpeaker RegistrationPoster Abstract SubmissionScheduleBrochureSocial Media ResourcesMeeting Resources
URL:https://sapagp.org/event/sapa-gp-2025-annual-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AC,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2024/12/Banner-Lanscape.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241119T153000
DTEND;TZID=America/New_York:20241119T190000
DTSTAMP:20260423T151455
CREATED:20241119T032716Z
LAST-MODIFIED:20241124T021507Z
UID:5207-1732030200-1732042800@sapagp.org
SUMMARY:The Philadelphia Biotech Job Fair 2024
DESCRIPTION:🛎 SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia) is pleased to partner with the Chamber of Commerce for Greater Philadelphia in supporting the Philadelphia Biotech Job Fair 2024\, an event dedicated to connecting talented professionals with leading biotech employers in the region. \n🗓️ Date & Time: November 19\, 2024\, from 3:30 PM to 7:00 PM \n📍 Location: The Curtis\, 601 Walnut St.\, Philadelphia\, PA 19106 \nThe Philadelphia Biotech Job Fair 2024\, hosted by BioLabs Philadelphia and BioStrategies Partners\, is recognized as one of the largest and most anticipated biotech career fairs in the Greater Philadelphia area. Over fifty prominent employers are expected to participate\, offering a unique platform for attendees to explore career opportunities\, network with industry leaders\, and learn about current trends in biotechnology and pharmaceuticals. \nFor further details\, please visit the official event website: phillybiotechjobsfair.com. \nSubscribe to our newsletter and stay turned on our events! http://eepurl.com/GUcq1 \nRecap on LinkedIn.
URL:https://sapagp.org/event/the-philadelphia-biotech-job-fair-2024/
LOCATION:PA
CATEGORIES:Event,In Person
ATTACH;FMTTYPE=image/avif:https://sapagp.org/wp-content/uploads/2024/11/RGB-logo_edited.avif
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240614T080000
DTEND;TZID=America/New_York:20240615T170000
DTSTAMP:20260423T151455
CREATED:20240823T003107Z
LAST-MODIFIED:20240823T005018Z
UID:5145-1718352000-1718470800@sapagp.org
SUMMARY:SAPA-GP 2024 CGT
DESCRIPTION:
URL:https://sapagp.org/event/sapa-gp-2024-cgt/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2024/08/Capture-1.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240411T090000
DTEND;TZID=America/New_York:20240411T103000
DTSTAMP:20260423T151455
CREATED:20240406T222308Z
LAST-MODIFIED:20240406T222308Z
UID:5013-1712826000-1712831400@sapagp.org
SUMMARY:BioVerse - Where Science Sparks Business - Recap of AACR2024
DESCRIPTION:REGISTER HEREJoin Bioverse webinar episode 8 to review the exciting presentations from AACR 2024 in San Diego. Our experts of cancer research and drug development will share will discuss: \n\nThe industry-shaping data of ADC and radiopharmaceutical\nClinical data from cell therapy\, bispecific antibody\, cancer vaccine\, targeted therapy\, and other drug classes\nNovel targets and industry-shaping scientific breakthroughs\nPractice-changing or market-moving clinical trial data\nHighlights of presentations from Asian biotech companies\n\nAbout the Speakers\nLihua Yu\, PhDChief Data Officer\, LifeMine TherapeuticsAs LifeMine’s Chief Data Officer\, Lihua brings vast experience in drug discovery from target identification to translational medicine\, data science\, and early clinical development. Lihua is passionate about integrating and applying data science across R&D\, partnering with all functions to drive the platform and pipeline forward.\nLihua comes from Fog Pharma where she was leading the Data Science function and co-leading the discovery platform and new targets. Prior to Fog\, Lihua was at H3 where she first served at head of bioinformatics\, later as Chief Data Science officer and President. Preceding H3\, Lihua was the cancer bioinformatics leader at AstraZeneca Oncology US.\nLihua holds a Ph.D. in biomedical engineering from Boston University\, studying under Dr. Temple Smith\, and M.E. and B.E. in biomedical engineering from Tsinghua University in Beijing\, China.Cassian Yee\, MDProfessor & Scientific Founder\, MD Anderson Cancer Center & Mongoose BioDr. Yee is a Professor in the Division of Cancer Medicine\, Director of the Program in TCR-based Therapeutics and Co-Director of the Adoptive Cellular Therapy Platform at UT MD Anderson Cancer Center.\nHe is an elected member of the American Society of Clinical Investigator\, former co-Leader of the Stand Up to Cancer- AACR/CRI Dream Team and recipient of Damon Runyon Cancer Research Foundation Physician Scientist award\, and the Rao Potul Basic Science Award. He holds an endowed position as the Kenneth Muller Professorship of Melanoma Research. Over the last 20+ years\, Dr. Yee has pioneered a form of ACT\, known as Endogenous T Cell (ETC) therapy\, using peripheral blood to generate a uniform population of antigen-specific memory T cells. He has conceived and executed several IND-approved first-in-human clinical studies establishing principles of T cell persistence\, memory and antigen-spreading He is corresponding or lead author in > 80 publications\, including The New England Journal of Medicine\, Nature\, Science\, Science Immunology\, Science Translational Medicine\, Nature Medicine\, Journal of Clinical Oncology\, Journal of Experimental Medicine\, Gastroenterology and Cancer Immunology Research. He holds > 15 worldwide patents on ex vivo generation of antigen specific T cells\, memory reprogramming\, and antigen discovery and seeks to extend immunotherapy-based cancer treatments globally.\nHe is scientific co-founder of Immatics US and is the founder of Mongoose Bio\, an early stage cell therapy company poised to treat patients with gastric\, esophageal\, lung \, breast bladder\, ovarian\, uterine and other cancers.Jeff Bockman\, PhDEVP & Expert Advisor\, Oncology\, LumanityJeff leads the Oncology and Virology Practices at Lumanity. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth licensing opportunity and valuation assessments during his tenure at Cello Health BioConsulting\, now Lumanity. He often speaks at conferences on scientific and commercial issues in cancer\, especially immuno-oncology.\nBefore joining Cello Health BioConsulting\, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients – Dr. Sidney Altman on ribozymes\, and Dr. Stanley Prusiner on prions – and holds four patents in the use of ribozymes.\nHe received a BA from University of California at San Diego\, a PhD in Medical Microbiology from the University of California at Berkeley\, and an MA in English/Creative Writing from New York University.\nJeff is a member of the American Association for Cancer Research (AACR)\, the American Society of Clinical Oncology (ASCO)\, the American Society of Hematology (ASH)\, the American Society of Gene and Cell Therapy (ASGCT)\, the Society for Immunotherapy of Cancer (SITC) and the New York Academy of Sciences (NYAS).\nJeff is a mentor for the NCI Innovation Conference\, a judge for the Citeline Awards\, an advisor to the JPM Biotech Showcase\, a member of the Advisory “Group” to Skipper Bio Med (a preclinical research consultancy that provides pro bono services to academic and industry groups\, developing promising lung and/or pancreatic cancer therapeutics/device. Skipper is fully supported by a private US family that has been personally impacted by these cancers and is committed to bridging the research “valley of death”).\nJeff is also part of the Clinical Advisory Board of ImmunOS (an immunotherapy company based in Zurich) and the Scientific Advisory Board of hC Bioscience (a novel RNA-based platform company in Cambridge\, MA).
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-recap-of-aacr2024/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2024/04/webinar-4-11-2024-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240308T140000
DTEND;TZID=America/New_York:20240309T180000
DTSTAMP:20260423T151455
CREATED:20240103T191713Z
LAST-MODIFIED:20240310T124756Z
UID:4701-1709906400-1710007200@sapagp.org
SUMMARY:SAPA-GP 2024 Annual Conference
DESCRIPTION:SAPA-GP 2024 Annual Conference: \nInnovating Biopharma Frontier\nA Path to Growth and Impact\nREGISTER NOWSocial Media ToolKitAGENDAMarch 8th – 9th\, 2024 (In-Person)\nSheraton Valley Forge Hotel\n480 N Gulph Rd\, King of Prussia\, PA 19406\n*Notes: The main conference is on Saturday only. An AI and Data science workshop will be offered on Friday afternoon as an add-on option which needs to be purchased separately.\nClick here to register.\nSAPA-GP is thrilled to invite you to participate in the 2024 SAPA-GP Annual Conference “Innovating the Biopharma Frontier: A Path to Growth and Impact”\, which will be held on Friday\, March 8th\, and Saturday\, March 9th\, at the Sheraton Valley Forge Hotel. The SAPA-GP Annual Conference is a great platform for participants to share their knowledge\, best practice\, and viewpoints on important issues and current trends in life science industries. The event typically features presentations and panel discussions from over 70 distinguished speakers and panelists from academia\, industry\, and regulatory agencies. It also provides opportunities for pharmaceutical science and public health education\, networking\, career development\, and business partnerships. \nBuilding on the past success\, we believe this year’s event will be enhanced owing to the participation of many distinguished speakers. This year\, our conference will cover diverse topics including the following areas with a highlight on biologics: \n\nAdvances in discovery and development of evolving biotherapeutics\nEnabling technology to accelerate clinical development\nTurbocharging innovation in biologics drug product and manufacturing\nThe AI & Data Sciences Frontier to Elevating Pharmaceutical Innovation\nInvestment and Business Development\nCareer Development\n\nFounded in 2002\, SAPA-GP remains dedicated to advancing pharmaceutical sciences and biotechnology\, encouraging scientific and business collaboration\, and nurturing the career development of pharmaceutical professionals\, with a strong emphasis on biologics. With over 4\,000 members\, we play a crucial role in shaping favorable business environments in the Greater Philadelphia area. We express our deep gratitude for your support of SAPA-GP and your expertise in biologics. Your participation will be greatly appreciated. \nCheck out our list of top-notch speakers:We highly appreciate the following sponsors:REGISTER NOWStay tuned for more speakers and agenda. \nBecoming our Annual Conference sponsors with these benefits:\n• Exhibition booths at the Annual Conference\n• Company showcases in the conference brochure and website\n• Guest speaker slots in parallel sessions\n• A platform for reaching out to potential business partners\n• Far-reaching market penetration via email blasts\, LinkedIn\, and WeChat groups\n• Great opportunities for talent recruitment… and more! For sponsorship opportunities\, please contact: bd@sapa-gp.org \nDo you want to become a Volunteer for SAPA-GP Annual Conference and future events? please contact: sapagp@sapa-gp.org \nRefer to our website for the Refund and Transfer policy and Student Discount. \nSAPA-GP\, supported by the collective wisdom of professionals in the pharmaceutical industry\, strives to shine insight into how the pharmaceutical industry is adapting to the evolving environment and transforming itself into the new era of biopharma 2.0. The SAPA-GP 2024 Annual Conference will be a unique opportunity for people to come together to celebrate the transformation underway\, and more importantly\, to brainstorm how to ride the tide to success. \nCheck out more events on SAPA-GP website or scan the QR code below.
URL:https://sapagp.org/event/sapa-gp-2024-annual-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AC,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2024/01/AC2024-featured.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240214T083000
DTEND;TZID=America/New_York:20240214T093000
DTSTAMP:20260423T151455
CREATED:20240205T142753Z
LAST-MODIFIED:20240205T142753Z
UID:4788-1707899400-1707903000@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Feb 2024
DESCRIPTION:REGISTER HEREThis panel of decorated physician scientists have brought about a dozen of drugs to the market and have collectively accumulated 70 years of industry drug development experience. The approved drugs (e.g.\, YEROVY\, KEYTRUDA\, ZEJULA\, JEMPERLI\, BLENREP\, TZIELD\, TREMFYA\, ORENCIA\, NULOJIX\, FASENRA etc) span from immuno-oncology\, precision-oncology\, ADC\, autoimmune diseases\, diabetes\, dermatology\, to COVID\, during their executive roles at Merck\, JNJ\, AstraZeneca\, BMS\, GSK\, Sanofi\, and a number of biotechs. Many of the biotechs were founded our panelists and later acquired by biopharmas.  \nThis is the ideal panel to share the “Checklists”\, or best practice\, behind this stellar track record of approved drugs. Additionally\, they will also share the secret sources of some turn-around stories and their advice to emerging biotechs\, especially the China biotechs\, that aspire to develop innovative medicines for the global market and patients around the world. \nAbout the speakers:Axel Hoos\, MD/PHD.CEO of Scorpion TherapeuticsAxel Hoos is a physician-scientist\, biopharma leader\, and entrepreneur. Most recently\, Dr. Hoos served as CEO of Scorpion Therapeutics a next-generation biotechnology company focused on Precision Oncology 2.0\, and as Senior Vice President\, R&D Governance Chair\, and Therapeutic Area (TA) Head for\nOncology at GSK\, leading the re-building of the Oncology Division after its divestment to Novartis in 2015.\nPreviously\, Dr. Hoos served as Executive Chair of the Board of the Sabin Vaccine Institute (SVI)\, a global health organization\, overseeing its organizational re-structuring and renewal of R&D strategy\, and as the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS)\, where he and his team developed Yervoy® (ipilimumab)\, the first checkpoint inhibitor drug\, and created the term Immuno-Oncology together with a new development paradigm to\ncharacterize the interplay of the immune system and cancer in the context of\nimmunotherapy drug development.\nDr. Hoos also served as Director on the Boards of biotechnology companies NextPoint Therapeutics\, and TCR2\, and Co-Founder and Director of Imugene. He further served as Co-Director of the Cancer Immunotherapy Consortium (CIC)\, Scientific Advisory Board Member of the Cancer Research Institute (CRI)\, and Co-Founder and Executive Committee member of the Partnership for Accelerating Cancer Therapies (PACT) of the Biden Cancer Moonshot.\nOver his career\, Dr. Hoos’ efforts aimed at the advancement of medicine and science into new territories\, the development of transformational therapies for patients with life threatening diseases\, and business and scientific partnerships. Francisco Leon\, MD\, PhDFounder and CEO of Tolerance BioFrancisco Leon is the Founder and CEO of Tolerance Bio\, focused on restoring and preserving the function of the thymus. He is also the Co-founder and Chairman of Paulex Bio\, focused on prevention and treatment of diabetes.\nFrancisco is a clinical and basic immunologist with a long career in academia (NIH)\, biopharma (BMS\, MedImmune/AZ\, Janssen/JNJ) and as an entrepreneur – as CEO\, CMO and CSO of several companies.\nHe has led or participated in the development of 6 drugs which reached the market\, most recently teplizumab (TZIELD®) for the delay or prevention of the onset of clinical type 1 diabetes\, and has co-founded two biotech companies acquired by Pharma: Celimmune\, acquired by Amgen in 2017\, and Provention Bio\, acquired by Sanofi in 2023.David Weinstock\, MD/PhDVice President of Discovery Oncology\, MerckDavid Weinstock joined Merck/MSD in January 2022 as the Vice President of Discovery Oncology and is based in Boston. In that role\, he leads the global preclinical effort to develop novel agents for patients with cancer. Dr. Weinstock was previously the Lavine Family Professor at Dana-Farber Cancer Institute\, a Professor of Medicine and Pediatrics at Harvard Medical School\, and a National Cancer Institute Outstanding Investigator. He completed fellowship training in Medical Oncology and Infectious Diseases at Memorial Sloan-Kettering Cancer Center. He joined the staff of Dana-Farber Cancer Institute and Brigham and Women’s Hospital in 2008\, where he saw patients as a medical oncologist and directed a translational research program focused on novel therapeutics for lymphoid malignancies.ModeratorLi Yan\, MD/PhD Li Yan is a seasoned drug developer. He held executive positions at Brii Biosciences\, GSK\, Merck\, and Johnson & Johnson. He has contributed to and overseen the development and approval of many medicines to include amubarvimab and romlusevimab for COVID\, Zejula™\, Keytruda™\, and Blenrep™.  His passion is to bring innovative medicines to transform patients’ lives\, especially those in underprivileged communities.  He firmly believes in the power of global collaboration. Li is a graduate of Peking University Medical College where he served as an adjunct professor\, and University of Kansas Medical School. He received his post graduate training at Harvard Medical School and is an alumnus of Harvard Business School Enterprise Leadership program. Li serves as an adjunct professor at Yonsei University\, South Korea.Webinar HostLeon ‘Jun’ Tang\, PhDFounding partner of InScienceWeTrust BioAdvisoryLeon ‘Jun’ Tang\, is the founding partner of InScienceWeTrust BioAdvisory\, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community\, which has more than 2\,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.\nDr. Tang serves as a scientific advisor to Mianus Capital\, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark\, an Asian biotech professional’s association based in Massachusetts.\nPreviously\, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech\, a public biotech listed on Hong Kong Stock Exchange\, a biotech sell-side analyst at Barclays Investment Bank\, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.\nDr. Tang has published 50+ academic papers\, some of which are in Nature Reviews Drug Discovery\, Lancet Oncology\, Science Translational Medicine\, Nature Communications\, Science Advances\, PNAS\, etc. Dr. Tang received his bachelor’s degree from Tianjin University\, master’s degree from Nankai University\, PhD from Icahn School of Medicine of Mount Sinai\, and postdoctoral training at Memorial Sloan Kettering Cancer Center.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-feb-2024/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2024/02/0214_webinar_featured-transformed.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240111T200000
DTEND;TZID=America/New_York:20240111T210000
DTSTAMP:20260423T151455
CREATED:20231227T195252Z
LAST-MODIFIED:20231227T195252Z
UID:4689-1705003200-1705006800@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Jan 2024
DESCRIPTION:REGISTER HERETong ZhangPh.D.\, CBO/CFO & Co-Founder\, VelaVigoTong Zhang\, PhD. Dr. Tong Zhang is the co-founder\, CBO/CFO of VelaVigo. Prior to VelaVigo he was Chief Business Officer at Shanghai Genechem\, Managing Director at C-Bridge Capital (CBC)\, a healthcare focused PE\, responsible for sourcing\, evaluation and execution of investment opportunities focusing on China market\, as well as incubating and managing portfolio companies.\nPrior to CBC Tong was head of Corporate BD at WuXi AppTec\, responsible for strategic partnership and M&A\, head of Business Development for MSD China and pan-regional BD lead for at Merck & Co.\, head of Business Development at EKR Therapeutics\, a VC-backed specialty pharmaceutical company in the US. Tong also had investment experience as a Director at ESP Equity Partners\, and equity analyst covering the US pharmaceutical industry for Credit Suisse in New York. Tong worked as a consultant for ISO HealthCare Consulting (now part of the Monitor Group) and Defined Health\, leading strategy consulting firms in the biopharmaceutical industry.\nTong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.Jing YangPh.D.\, CSO & Co-Founder\, BaseCure TherapeuticsJing Yang\, Ph.D.\, Chief Scientific Officer\, BaseCure Therapeutics， Jing currently serves as the Chief Scientific Officer\, Co-founder and Board Director of BaseCure Therapeutics，a siRNA therapeutic startup company with proprietary platform technology and a rapidly growing pipeline. Jing is an accomplished drug hunter with over 20 years of experience leading multidisciplinary discovery research teams. In her previous roles at Johnson & Johnson and Bristol-Myers Squibb\, Jing led the progression of numerous innovative drugs through the pipeline and successfully delivered three IND candidates for clinical research. Her expertise spans from small molecules\, biologics\, stem cells to RNAi research. Jing also held a number of leadership roles in Corporate and Non-Profit Organizations\, most notably the Global Lead of Pan Asian Network at Bristol-Myers Squibb in 2019-2021 and President of Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) in 2019-2020.\nJing received her BS degree in Physical Chemistry at Sichuan University in China and her Ph.D degree in Glycobiology at Albert Einstein College of Medicine in New York. After completing her postdoctoral trainings at New England Medical Center and University of Pennsylvania\, Jing held an Instructor position at the Center for Experimental Therapeutics and Department of Pharmacology at University of Pennsylvania. Jing is an author of 40 peer reviewed manuscripts and inventor of 14 patent applications.Lee QianCFA\, Investment Manager\, Baillie GiffordLee QIAN. Lee Qian is an investment manager at Baillie Gifford’s Positive Change Strategy. He joined Baillie Gifford in 2012 and is a CFA Charterholder. Lee graduated BA (Hons) in Economics and Management from the University of Oxford in 2012. Lee has a keen interest in sustainable development\, across a range of topics including health\, climate\, and education. All views expressed will be his own.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-jan-2024/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/12/2024-Jan-11-webinar-featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240111T120000
DTEND;TZID=America/New_York:20240111T130000
DTSTAMP:20260423T151455
CREATED:20231218T234511Z
LAST-MODIFIED:20231218T234511Z
UID:4684-1704974400-1704978000@sapagp.org
SUMMARY:Job Seekers Roundtable Virtual Meeting
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/job-seekers-roundtable-virtual-meeting/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/12/job-seeker-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240109T200000
DTEND;TZID=America/New_York:20240109T210000
DTSTAMP:20260423T151455
CREATED:20231218T234013Z
LAST-MODIFIED:20231218T234013Z
UID:4675-1704830400-1704834000@sapagp.org
SUMMARY:How to Write Effective Email Virtual Workshop
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/how-to-write-effective-email-virtual-workshop/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/12/effective-email-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231213T083000
DTEND;TZID=America/New_York:20231213T093000
DTSTAMP:20260423T151455
CREATED:20231119T234957Z
LAST-MODIFIED:20231120T003151Z
UID:4661-1702456200-1702459800@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Dec 2023
DESCRIPTION:Register HereLes FuntleyderCFO\, Investor\, Professor\, AuthorMr. Funtleyder has a 20-year track record of healthcare investing and is currently a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. While at E squared Les has had five IPO exits including serving as CFO of one of the portfolio companies.\nPrior to E Squared\, Mr. Funtleyder was the Director of Strategic Investments and Communications for Opko Health. In this role he participated in over $2 billion in transactions including acquisitions\, strategic investments\, and licensing deals. He also led all corporate and product communication efforts for the $5 billion company.\nLes was a long-time portfolio manager and healthcare strategist for the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX) a mutual fund dedicated to investing in transformative healthcare companies.\nHe joined Miller Tabak\, after managing a healthcare portfolio for Provident Advisors\, a hedge fund in Minneapolis\, Minnesota. Before joining Provident\, Les worked as a medical device analyst at UBS Warburg. He also covered Biotechnology stocks at Bigelow and Company. His industry experience includes directing clinical and business research at Innovative Health Solution\, a joint venture of Merck and Wyeth\, and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. He started his healthcare career at Empire Blue Cross/Blue Shield where he developed his approach to determining how products and services should get reimbursed\, a skill that is vital in making healthcare companies successful.\nMr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma\, Biotech\, and Health Care Services (McGraw Hill)\, which bridges the gap between health reform\, innovation and investing. He is widely quoted in the Wall Street Journal\, the New York Times\, and the Financial Times\, and is a frequent guest on CNBC\, Bloomberg and NPR for his perspective on the healthcare sector and its constituent companies. He is also a consulting partner to Bluecloud Health\, a Sub-Saharan healthcare private equity fund and an advisor to Zentalya\, a venture capital firm focused on South American healthcare. He currently sits on the Board of Directors for Applied Therapeutics (NASDAQ: APLT) and Reviva Pharma (NASDAQ: RVPH).\nLastly\, Les is currently an Adjunct Professor of Public Health at Columbia University. Les earned his Master of Public Health from Columbia University Mailman School of Public Health\, and studied English and Economics at Tulane University.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-dec-2023/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/11/1213-webinar-featured-1.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231108T080000
DTEND;TZID=America/New_York:20231108T170000
DTSTAMP:20260423T151455
CREATED:20231031T152125Z
LAST-MODIFIED:20231031T152125Z
UID:4646-1699430400-1699462800@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Nov 2023
DESCRIPTION:REGISTER NOWNikhil Mutyal\, Ph.D.Executive Director\, Business Development and Licensing\, Pacific Hub\, Merck and Co.Nikhil Mutyal\, Ph.D. is Executive Director\, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology\, Neuroscience and Cardiometabolic diseases for therapeutic opportunities from companies and research initutes based in Western US/CAN\, SE Asia\, ANZ. Dr. Mutyal’s professional career spans across management consulting for pharma/biotech and BD roles across various companies. Dr. Mutyal received his Ph.D. in Biomedical Engineering (Cancer Research) from Northwestern University and has B.S.+M.S. in Medicinal Chemistry from Indian Institute of Technology\, Kanpur.Yang Qiu\, Ph.D.Chief Scientific Officer and US GM\, Duality BiologicsDr. Yang Qiu has over 20 years of MNC drug discovery and development experience with demonstrated success of leading drug discovery\, translational medicine and early clinical development programs. She contributed to the discovery and progression into clinic of over 15 drug candidates and drug approvals including the most recent FDA BTD Patritumab Deruxtecan (HER3-DXd) \nPreviously as Co-chair of cross-ADC program\, Senior Director of Translational Medicine at Daiichi Sankyo; Director\, Head of Translational and Biomarker Research at Janssen; Director\, Head of Molecular Discovery Research at GSK China\nPostdoc in Human Genomics at Lawrence Berkeley National Lab\, PhD in Molecular Biology from University of Texas at Austin\, and college from University of Science and Technology in ChinaLiang Xiao\, Ph.D.COO and Co-founder\, MediLink TherapeuticsDr. Liang Xiao is the COO and Co-founder of MediLink Therapeutics. Dr. Liang Xiao is primarily responsible for ADC drug preclinical development and external cooperation in business development at MediLink. With 16 years of experience in both academia and the biopharmaceutical industry\, Dr. Xiao previously served as the VP of Biologics R&D at Kelun-Biotech\, where he was responsible for the development of multiple innovative biologics from 2013 to 2020. These projects resulted in global licensing agreements with multinational companies\, totaling over $12 billion in value. \nDr. Xiao has successfully led 15 monoclonal antibody\, bispecific antibody\, and ADC projects into clinical stages. Among them\, two monoclonal antibody projects and one ADC project have been submitted for BLA. Additionally\, one ADC project is currently in Phase III clinical stage\, and four ADC projects are in Phase I clinical stage. \nDr. Xiao holds a Bachelor’s degree in Life Sciences from the University of Science and Technology of China\, as well as a Ph.D. degree in Chemical Engineering from the University of Southern California.Shunfei Yan\, Ph.D.Medical Evaluation Manager\, AstraZeneca ChinaShunfei is currently a medical evaluation manager at AZ China where he is responsible for searching & evaluating potential external partnership opportunities. Before joining AZ\, Shunfei spent multiple years in venture capital domain where he served as an investment manager at Fosun Health Capital and Lingang Wonder-of-Land Capital with a focus on innovative medicines. Shunfei received his PhD degree in oncology from the University of Melbourne where he conducted his study in synthetic lethality. Before that\, he obtained his Master and Bachelor degree in Biological Sciences from Fudan University.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-nov-2023/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/10/Nov-webinar-featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231010T100000
DTEND;TZID=America/New_York:20231010T110000
DTSTAMP:20260423T151455
CREATED:20231003T160044Z
LAST-MODIFIED:20231031T150006Z
UID:4636-1696932000-1696935600@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Oct 2023
DESCRIPTION:Register NowChris Sheldon Ph.D.Dr. Chris Sheldon is among the best biopharma dealmakers\, and his impressive track record includes AstraZeneca/Daiichi’s ~$13bn partnership of DS8201 and Dato-Dxd\, AstraZeneca’s $6.4b acquisition of Acerta over its Acalabrutinib\, which is included in the sensation book “In Blood and Money”\, during his time at AstraZeneca as the head of Oncology BD. Shortly after he took the helm of the GSK’s BD\, he led the $2B acquisition of Bellus Health and also closed the deal with WuXi Biologics over their multiple bi- & multi-specific T cell engagers for oncology.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business-oct-2023/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/10/featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231008T110000
DTEND;TZID=America/New_York:20231008T150000
DTSTAMP:20260423T151455
CREATED:20230919T000606Z
LAST-MODIFIED:20230919T000606Z
UID:4625-1696762800-1696777200@sapagp.org
SUMMARY:SAPA-GP 2023 Fall Picnic
DESCRIPTION:register now
URL:https://sapagp.org/event/sapa-gp-2023-fall-picnic/
LOCATION:Upper Providence Blackrock Park\, 1286 Black Rock Road\, Phoenixville\, PA\, 19460\, United States
CATEGORIES:Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/09/https___cdn.evbuc_.com_images_594364999_202745421483_1_original.jpeg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230920T210000
DTEND;TZID=America/New_York:20230920T220000
DTSTAMP:20260423T151455
CREATED:20230907T144313Z
LAST-MODIFIED:20231003T154735Z
UID:4617-1695243600-1695247200@sapagp.org
SUMMARY:BioVerse: Where Science Sparks Business Sept 2023
DESCRIPTION:This event has ended. Please scroll down for the recording.Catherine PearceDHSc\, MBADr. Pearce started her career in 1997 at Hoffman-LaRoche\, then at Merck launching therapeutics in the cardiovascular space. In 2001\, Dr. Pearce joined a small CRO\, Medpace\, as a Clinical Project Manager. She led hundreds of global Phase 1-4 studies in a variety of therapeutic areas\, including neurology\, diabetes\, lipid-lowering\, kidney diseases\, and obesity. She started the first business development team and marketing teams at Medpace in 2011. In 2013\, Dr. Pearce joined Teva as VP\, R&D\, leading a new division dedicated to evaluating generics for repurposing. One of the most recognizable efforts to come from this program was the approval of Uzedy in 2023 for the treatment of schizophrenia. Uzedy was approved in partnership with Medincell\, which was a collaboration her team had spearheaded. In 2015\, Dr. Pearce decided to come back to her hometown of Cincinnati\, OH to co-found a biotech incubator\, CinRx. The idea of launching a biotech portfolio company seemed timely Dr. Pearce: the thesis was to take early-stage or “shelved” assets from pharma\, biotech\, or academia and develop them through proof-of-concept to be acquired by large pharma with commercial capabilities. During her time at CinRx\, Dr. Pearce developed 6 “Cin” portfolio companies in areas such as oncology\, obesity\, gastroparesis\, and hypertension. When CinCor’s Board decided the strategic exit of this company’s novel aldosterone synthase inhibitor was a public offering\, Dr. Pearce spun out with the organization to build the company’s infrastructure and help take it public. After the asset\, baxdrostat\, demonstrated its value in the Phase 2 BrigHtn study published in the New England Journal of Medicine\, the company was eventually acquired by AstraZeneca in February 2023 in a transaction worth up to $1.8B.\nToday\, Dr. Pearce is once again embarking on the idea that forming a company around early-stage or shelved assets is a necessary endeavor. This time\, though\, she is using her experience to build stronger clinical development teams\, Advisory Boards\, strategic partners\, and financial backers to evaluate novel therapeutics and design the ideal trials to demonstrate the benefits and safety of life-saving medicines for the patients that need them. As the CEO of newly formed JucaBio\, she is excited about the future of drug development and the possibilities of bringing additional therapeutics to patients worldwide in areas of high unmet medical needs.\nIn addition to sitting on a number of private biotech Boards\, Dr. Pearce is an advisor to several start-ups and a Board of Trustee Member at Xavier University\, where she received her undergraduate education and MBA. She received her Doctorate in Health Sciences from Nova Southeastern University. Dr. Pearce is married with 3 children and is a fitness enthusiast\, book lover\, traveler\, and avid cook. Dr. Pearce lives by three creeds: say “yes” many more times than you say “no\,” never ask someone to do work you are unwilling or unable to do yourself\, and — importantly — always look for a little fun along the way.
URL:https://sapagp.org/event/bioverse-where-science-sparks-business/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/09/featured-image-9-20-2023-webinar.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230727T200000
DTEND;TZID=America/New_York:20230727T213000
DTSTAMP:20260423T151455
CREATED:20230714T154859Z
LAST-MODIFIED:20230714T154859Z
UID:4564-1690488000-1690493400@sapagp.org
SUMMARY:Beyond FDA Approval: Assessing Pharmaceutical Market Access Risk for Drug Development Strategy
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/beyond-fda-approval-assessing-pharmaceutical-market-access-risk-for-drug-development-strategy/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/07/0727-webinar-feature.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230623
DTEND;VALUE=DATE:20230625
DTSTAMP:20260423T151455
CREATED:20230607T230200Z
LAST-MODIFIED:20230607T230200Z
UID:4537-1687478400-1687651199@sapagp.org
SUMMARY:2nd Annual SAPA-GP @Philly Cell Gene Therapy Conference
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/2nd-annual-sapa-gp-philly-cell-gene-therapy-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AtPhilly,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/06/cgt_featuered.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230609T210000
DTEND;TZID=America/New_York:20230609T223000
DTSTAMP:20260423T151455
CREATED:20230607T004735Z
LAST-MODIFIED:20230607T004735Z
UID:4531-1686344400-1686349800@sapagp.org
SUMMARY:ASCO2023 Recap: The Winners\, Losers\, and Black Horses
DESCRIPTION:REGISTER HERE
URL:https://sapagp.org/event/asco2023-recap-the-winners-losers-and-black-horses/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/06/ASCO_featured_recap.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230530T210000
DTEND;TZID=America/New_York:20230530T223000
DTSTAMP:20260423T151455
CREATED:20230526T142648Z
LAST-MODIFIED:20230526T142648Z
UID:4495-1685480400-1685485800@sapagp.org
SUMMARY:Preview of ASCO by BioSpark/ISWTC/SAPA-GP
DESCRIPTION:REGISTER HERESpeakersModeratorOrganizers
URL:https://sapagp.org/event/preview-of-asco-by-biospark-iswtc-sapa-gp/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/05/featuered-image.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230517T180000
DTEND;TZID=America/New_York:20230517T203000
DTSTAMP:20260423T151455
CREATED:20230514T002908Z
LAST-MODIFIED:20230514T005959Z
UID:4465-1684346400-1684355400@sapagp.org
SUMMARY:@Philly Company Showcase & Networking Dinner
DESCRIPTION:
URL:https://sapagp.org/event/philly-company-showcase-networking-dinner/
LOCATION:Jin Ding Restaurant\, 1051 Conestoga Rd\, Bryn Mawr\, PA\, 19010\, United States
CATEGORIES:AtPhilly,Career Events,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/05/pdf_20230510_095448_0000.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230331T120000
DTEND;TZID=America/New_York:20230401T190000
DTSTAMP:20260423T151455
CREATED:20230118T023035Z
LAST-MODIFIED:20230329T122928Z
UID:4163-1680264000-1680375600@sapagp.org
SUMMARY:SAPA-GP 2023 Annual Conference
DESCRIPTION:SAPA-GP 2023 Annual Conference: Embracing New Technologies in a Changing World \nRegister NowAgendaMarch 31st – April 1st\, 2023 (In-Person)\nSheraton Valley Forge Hotel\n480 N Gulph Rd\, King of Prussia\, PA 19406\nClick here to register or scan the QR code on the right.\nDuring the past few years\, the pharmaceutical industry has experienced dramatic changes due to COVID 19 pandemic and technological advancements.  Many of those changes are transforming the industry and speeding up the pace of new drug development. On the technological front\, new drug targets have been discovered at ever increasing speed. AI assisted drug discovery is opening new frontiers. Digital technologies\, decentralized clinical studies\, and real-world evidence are reshaping clinical development. On the business front\, creative business models are weathering the current market downturn and rejuvenating fresh investment\, mergers and acquisitions (M&A)\, and partnership around the world. Regarding patient access\, in responding to skyrocketing price tags of new drugs\, adaptive payment mechanisms have been devised in hope of delivering lifesaving medicines to patients in a sustainable way. \nOn Mar 31st – Apr. 1st\, 2023\, SAPA-GP will hold 2023 annual conference at King of Prussia\, PA. There will be 5 Parallel Tracks: \n\nScientific: Pioneering a New Era of Drug Discovery & Development: Novel Targets\, Innovative Platforms\, and Recent Regulations\nClinical: New Trends in Clinical Development\nBusiness: The Business Engine of New Drug Development: Fundraising\, BD\, and Commercialization\nMarket Research: Promoting Patient Access after Regulatory Approval\nCareer: Career Development\, Diversity\, Labor Law\, and Roundtable Discussion\n\nWe are excited to have Dr. Amir Kalali and Dr. Virginia Man-Yee Lee\, two well-known experts as our keynote speakers\, to share insights from both scientific and clinical perspectives. Moreover\, Dr. Tim Opler will discuss M&A transactions across the pharmaceutical industry\, and Dr. Joga Gobburu will talk about model-informed drug development. \nCheck out our list of top-notch speakers and sponsors: \nRegister NowStay tuned for more speakers and agenda. \nBecoming our Annual Conference sponsors with these benefits:\n• Exhibition booths at the Annual Conference\n• Company showcases in the conference brochure and website\n• Guest speaker slots in parallel sessions\n• A platform for reaching out to potential business partners\n• Far-reaching market penetration via email blasts\, LinkedIn\, and WeChat groups\n• Great opportunities for talent recruitment… and more! For sponsorship opportunities\, please contact: bd@sapa-gp.org \nDo you want to become a Volunteer for SAPA-GP Annual Conference and future events? please contact: sapagp@sapa-gp.org \nRefer to our website for the Refund and Transfer policy and Student Discount. \nSAPA-GP\, supported by the collective wisdom of professionals in the pharmaceutical industry\, strives to shine insight into how the pharmaceutical industry is adapting to the evolving environment and transforming itself into the new era of biopharma 2.0. The SAPA-GP 2023 Annual Conference will be a unique opportunity for people to come together to celebrate the transformation underway\, and more importantly\, to brainstorm how to ride the tide to success. \nCheck out more events on SAPA-GP website or scan the QR code below.
URL:https://sapagp.org/event/sapa-gp-2023-annual-conference/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AC,Event,In Person
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2023/01/banner.jpg
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230126T200000
DTEND;TZID=America/New_York:20230126T213000
DTSTAMP:20260423T151455
CREATED:20230119T131125Z
LAST-MODIFIED:20230120T033331Z
UID:4225-1674763200-1674768600@sapagp.org
SUMMARY:Humanized mouse models to accelerate drug development - SAPA-GP Webinar Jan 26\, 2023
DESCRIPTION:Register HereSanti s. ChenAssociate Director\, Immunology and Oncology\, GemPharmatechSanti is a research scientist and business development professional with over 10 years of experience in autoimmune disease\, immunology\, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology\, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia\, focusing on pediatric leukemia and therapies. Her projects include testing agents’ efficacy and mechanisms such as navitoclax\, venetoclax\, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.Sponsored by GemPharmatechGemPharmatech\, a leading provider of mouse models and preclinical services\, offers a one-stop solution for in vivo studies with a collection of more than 20\,000 strains including KO/cKO\, humanized\, disease\, germ-free and custom models\, as well as custom breeding services. \nSponsored by GemPharmatech; Contact: sales@gempharmatech.us
URL:https://sapagp.org/event/4225/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2023/01/Featured-pic.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221209T090000
DTEND;TZID=America/New_York:20221209T153000
DTSTAMP:20260423T151455
CREATED:20221201T171457Z
LAST-MODIFIED:20221201T173243Z
UID:4104-1670576400-1670599800@sapagp.org
SUMMARY:SAPA-GP Career Development Workshop
DESCRIPTION:Ignite Your Career GrowthWhat are your career goals for 2023? \n\nGet promoted?\nChange to a different role?\nBe more effective in your current role?\nMove from a technical to business role?\n\nIf so\, this Career Development Workshop is for YOU! \nCome learn and build your network \nREGISTER HERE!FEATURED SPEAKERSDavid CraginSenior Director\, Product ScienceTeva PharmaceuticalsCheryl PaesVP\, Head of MarketingCenter for Breakthrough MedicinesJing YangCo-founder & Board DirectorBaseCure TherapeuticsJamie HuangFounderPrinceton Leadership AcademyJoe LingleChief People OfficerCenter for Breakthrough MedicinesPan PanDirector of Business DevelopmentAkeso\, Inc.Audrey GreenbergCo-Founder & Chief Business OfficerCenter for Breakthrough MedicinesAgenda8:30am – 9:00am \n9:00am – 9:30am \nRegistration \nOpening remark & Keys to On-line and In-person networking \nDavid Cragin \nSenior Director\, Product Science \nTeva Pharmaceuticals \n9:30am – 10:00am \nTopic 1: The secrets of HR \nJoe Lingle \nChief People Officer \nCenter for Breakthrough Medicines \n10:00am – 10:30am \n1030am – 11:00am \nNetworking Break I \nTopic 2: Take a Chance on Unexpected Opportunities \nJing Yang \nCo-founder & Board Director \nBaseCure Therapeutics \n11:00am – 11:30am \nPanel Discussion \nAudrey Greenberg \nCo-Founder and Chief Business Officer \nCenter for Breakthrough Medicines \nJing Yang \nCo-founder & Board Director \nBaseCure Therapeutics \n11:30am – 1:00pm \n1:00pm – 1:40pm \nLunch Break \nTopic 3: Getting off the Sticky Floor \nJamie Huang \nFounder \nPrinceton Leadership Academy \n1:40pm – 2:00pm \n2:00pm – 2:40pm \nNetworking Break II \nTopic 4: A Path from R&D to Business Development \nPan Pan \nDirector of Business Dvelopment \nAkeso\, Inc \n2:40pm – 3:10pm \nPanel Discussion \nCheryl Paes \nVP\, Head of Marketing \nCenter for Breakthrough Medicines \nPan Pan \nDirector of Business Development \nAkeso\, Inc. \nScan QR code for registration\, or follow this registration link: \nhttps://www.eventbrite.com/e/sapa-gp-2022-career-development-workshop-igniting-your-career-growth-tickets-467770322627
URL:https://sapagp.org/event/sapa-gp-career-development-workshop/
LOCATION:The Center for Breakthrough Medicines\, 411 Swedeland Road\, #100\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:Career Events,Event,In Person,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2022/12/featured.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221110T200000
DTEND;TZID=America/New_York:20221110T213000
DTSTAMP:20260423T151455
CREATED:20221104T222406Z
LAST-MODIFIED:20221105T122416Z
UID:4080-1668110400-1668115800@sapagp.org
SUMMARY:Mouse Models for Disease Mechanism Studies and Drug R&D
DESCRIPTION:Register HereXiang Gao\, Ph.D.Founder and Chairman of GemPharmatechXiang Gao is an alumina of Nanjing University. He received his Ph.D. degree from Thomas Jefferson University in 1994\, then did his postdoctoral training at the Jackson Lab. In 2000\, Xiang was recruited back as professor at Nanjing University. Where he founded both Model Animal Research Center of NJU and National Resource Center of Mutant Mice of China. He was the associate dean of Medical School and director for the State Key Laboratory of Pharmaceutical Biotechnology. Xiang is the recipient for Cheung Kong Scholar from Ministry of Education and Distinguished Young Scholar from National Science Foundation. His lab has been focused on understanding the physiological homeostasis of metabolic and immunological processes. He has been funded by multiple national grants and published more than 200 research papers. Xiang is recipient of many national and international awards\, including the National Science and Technology Progress Award. In 2017\, Xiang founded GemPharmatech (GPT) which has become the leading company for animal model generation and application. GPT is the largest mutant mouse resource center in the world and now holds more than 22\,000 mutant mouse strains. GPT went IPO early this year at STAR market in Shanghai Exchange.Sponsored by: GemPharmatech\nGemPharmatech\, a leading provider of mouse models and preclinical services. With a collection of 20\,000+ strains\, GPT offers KO/cKO\, humanized\, disease\, and custom models\, as well as a one-stop solution for in vivo studies. Contact: brook.white@gempharmatech.us
URL:https://sapagp.org/event/mouse-models-for-disease-mechanism-studies-and-drug-rd/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/jpeg:https://sapagp.org/wp-content/uploads/2022/11/Nov.-10-Webinar-feature.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220915T200000
DTEND;TZID=America/New_York:20220915T213000
DTSTAMP:20260423T151455
CREATED:20220910T144808Z
LAST-MODIFIED:20220911T223208Z
UID:3944-1663272000-1663277400@sapagp.org
SUMMARY:Accelerating Cell & Gene Therapy Innovations: NK Cell Therapy\, Preclinical Solutions\, and CRO
DESCRIPTION:Register HereDongfang LiuAssociate Professor/Director of Immunoassay Development ProgramDongfang Liu\, Ph.D.\, an Associate Professor and Director of Immunoassay Development Program at the Department of Pathology\, Immunology and Laboratory Medicine in Rutgers University- New Jersey Medical School. In 2012\, Dr. Liu was recruited to Baylor College of Medicine as a tenure-track Assistant Professor in the Department of Pediatrics\, and Pathology & Immunology\, before joining Houston Methodist Research Institute (HMRI) as an Assistant Professor in 2015. In 2018\, Dr. Liu was promoted to an Associate Professor in HMRI. Dr. Liu did his Ph.D. and postdoctoral training on natural killer (NK) cells. After completing the postdoctoral training\, he joined Ragon Institute of MGH\, MIT and Harvard in 2011 as a senior research scientist\, where he worked on HIV-specific immune cell dysfunction. Dr. Liu’s research is primarily focused on the immunobiology of NK and chimeric antigen receptor (CAR)-NK cells. He has more than 20 years’ experience in NK cell research. Dr. Liu has published research papers in top-tier journals\, including Nature Immunology\, Immunity\, Nature Communications\, JACI\, Proc. Natl. Acad. Sci.\, and others. Dr. Liu serves on several editorial boards for multiple journals and as a reviewer for a number of journals and several grant agencies.Santi ChenAssociate Director\, Immunology and Oncology\, GemPharmatechSanti is a research scientist and business development professional with over 10 years of experience in autoimmune disease\, immunology\, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology\, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia\, focusing on pediatric leukemia and therapies. Her projects include testing agents’ efficacy and mechanisms such as navitoclax\, venetoclax\, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards. \nSponsored by GemPharmatechGemPharmatech\, a leading provider of mouse models and preclinical services. With a collection of 21\,000 strains\, GPT offers KO/cKO\, humanized\, disease\, and custom models\, as well as a one-stop solution for in vivo studies. \nContact: keila.woods@gempharmatech.us
URL:https://sapagp.org/event/accelerating-cell-gene-therapy-innovations-nk-cell-therapy-preclinical-solutions-and-cro/
LOCATION:PA
CATEGORIES:Event,Webex Meeting
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2022/09/Flyer-Sept-15_feature.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220617
DTEND;VALUE=DATE:20220619
DTSTAMP:20260423T151455
CREATED:20220428T020820Z
LAST-MODIFIED:20220911T023723Z
UID:3688-1655424000-1655596799@sapagp.org
SUMMARY:@Philly Cell & Gene Therapy Annual Conference 2022
DESCRIPTION:
URL:https://sapagp.org/event/philly-cell-gene-therapy-annual-conference-2022/
LOCATION:Sheraton Valley Forge Hotel\, 480 North Gulph Road\, King of Prussia\, PA\, 19406\, United States
CATEGORIES:AtPhilly,Event,In Person
ATTACH;FMTTYPE=image/png:https://sapagp.org/wp-content/uploads/2022/04/Screen-Shot-2022-04-16-at-08.29.05.png
ORGANIZER;CN="SAPA-GP":MAILTO:sapagp@sapa-gp.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220524T200000
DTEND;TZID=America/New_York:20220524T213000
DTSTAMP:20260423T151455
CREATED:20220511T191641Z
LAST-MODIFIED:20220911T022309Z
UID:3816-1653422400-1653427800@sapagp.org
SUMMARY:Finding your Pathway to Success - Career meeting
DESCRIPTION:Register Here
URL:https://sapagp.org/event/finding-your-pathway-to-success-career-meeting/
LOCATION:PA
CATEGORIES:Career Events,Event,Webex Meeting
END:VEVENT
END:VCALENDAR